Neprilysin Inhibitors and Bradykinin [PDF]
Frontiers in Medicine, 2018 Bradykinin has important physiological actions related to the regulation of blood vessel tone and renal function, and protection from ischemia reperfusion injury.
Duncan J. Campbell +2 more
doaj +4 more sources
IGF2BP1 Enhances Neprilysin mRNA Stability to Promote Proliferation, Invasion, and Angiogenesis in Placental Trophoblasts [PDF]
International Journal of General MedicineChengLing Fan,1,2 HongXia Zhou,2 YuFei Pan,3 Dan Lu1 1Medical College, Yangzhou University, Yangzhou, Jiangsu, 225009, People’s Republic of China; 2Department of Gynaecology and Obstetrics, Baoying Maternal and Child Health Hospital, Yangzhou, Jiangsu ...
Fan C, Zhou H, Pan Y, Lu D
doaj +2 more sources
Real-World Value of Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) in Korea: Moving From Cost-Effectiveness to Implementation. [PDF]
Korean Circ JKim TH.
europepmc +3 more sources
In Vivo Inhibition of Dipeptidyl Peptidase 4 and Neprilysin Activity Enables Measurement of GLP-1 Secretion in Male Rats. [PDF]
J Endocr SocGalsgaard KD +4 more
europepmc +2 more sources
Frontiers in Aging Neuroscience, 2021 Alzheimer’s disease (AD) is pathologically characterized by extracellular beta-amyloid (Aβ) plaques and intraneuronal tau tangles in the brain. A therapeutic strategy aims to prevent or clear these Aβ plaques and the Aβ-degrading enzyme neprilysin is a ...
Christian Humpel
doaj +1 more source
Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease [PDF]
Kidney Research and Clinical Practice, 2021 Despite significant advances in the management of heart failure with reduced ejection fraction (HFrEF), there remains an enormous health problem with high morbidity and mortality over the last few decades.
In-Jeong Cho, Seok-Min Kang
doaj +1 more source
Circulating Neprilysin Level Predicts the Risk of Cardiovascular Events in Hemodialysis Patients
Frontiers in Cardiovascular Medicine, 2021 Background: Neprilysin inhibition has demonstrated impressive benefits in heart failure treatment, and is the current focus of interest in cardiovascular (CV) and kidney diseases.
Hyeon Seok Hwang +9 more
doaj +1 more source
Soluble neprilysin and survival in critically ill patients
ESC Heart Failure, 2022 Background Critically ill patients admitted to an intensive care unit (ICU) exhibit a high mortality rate irrespective of the initial cause of hospitalization.
Max Lenz +10 more
doaj +1 more source
Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020 Background Neprilysin is a transmembrane endopeptidase involved in the breakdown of a variety of vasoactive peptides and serves as a therapeutic target in heart failure with reduced ejection fraction (HFrEF).
Suriya Prausmüller +8 more
doaj +1 more source
Biomedicines, 2021 Background: Alzheimer’s disease (AD) involves impairment of Aβ clearance. Neprilysin (NEP) is the most efficient Aβ peptidase. Enhancement of the activity or expression of NEP may provide a prominent therapeutic strategy against AD.
Dimitris Matiadis +7 more
doaj +1 more source